Results 161 to 170 of about 62,912 (312)

Refractory Palmoplantar Pustulosis Successfully Treated with JAK Inhibitor Tofacitinib: A Case Series

, 2023
Qingqing Xu, Xiaochen Wang, Anbo Yang, Wei Guo   +3 more
openalex   +2 more sources

P471 Real-world experience of using Tofacitinib in Ulcerative Colitis in biologic naïve and biologic exposed patients [PDF]

, 2022
Jonathan Cheesbrough, Mohammed Nabil Quraishi, Nandita Sharma, Islam Osama Nassar   +3 more
openalex   +1 more source

A Population‐Based Matched Cohort Study of Extra‐Digestive Cancer Incidence and Mortality in Individuals With and Without Inflammatory Bowel Disease

Alimentary Pharmacology &Therapeutics, EarlyView.
This illustration summarises our primary findings highlighting the rising incidence of certain extra‐digestive cancers among persons with IBD over the 25‐year study duration (left), and the relative rates of extra‐digestive cancer incidence and mortality among persons with IBD in recent years (2010–2019) compared to their age‐ and sex‐matched controls (
Sanjay K. Murthy, Faria Ahmed, Michael Pugliese, Monica Taljaard, Parul Tandon, Priscilla Matthews, Gilaad G. Kaplan, Stephanie Coward, Charles N. Bernstein, Eric I. Benchimol, M. Ellen Kuenzig, Laura E. Targownik, Harminder Singh, on behalf of the Canadian Gastro‐Intestinal Epidemiology Consortium (CanGIEC)   +13 more
wiley   +1 more source

SAT0304 TOFACITINIB INHIBITS TGF-Β1-INDUCED ACTIVATED CELL FUNCTIONS OF MYOFIBROBLAST IN HUMAN LUNG FIBROBLAST POPULATIONS [PDF]

, 2020
Fu Zhu, X. Zhang
openalex   +1 more source

Treatment options for immune‐related adverse events associated with immune checkpoint inhibitors

British Journal of Pharmacology, EarlyView.
Abstract The immunotherapy revolution with the use of immune checkpoint inhibitors (ICIs) started with the clinical use of the first ICI, ipilimumab, in 2011. Since then, the field of ICI therapy has rapidly expanded — with the FDA approval of 10 different ICI drugs so far and their incorporation into the therapeutic regimens of a range of malignancies.
Yu Hua Chen, Tamás Kovács, Péter Ferdinandy, Zoltán V. Varga   +3 more
wiley   +1 more source

S1‐Guideline for diagnosis and therapy of necrobiosis lipoidica

JDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.
Summary Necrobiosis lipoidica (NL) is a rare granulomatous skin disease of unknown etiology that occurs frequently in association with diabetes mellitus and other comorbidities. The predilection site is the lower leg, particularly the pretibial areas. The exact pathogenesis remains unclear.
Cornelia Erfurt‐Berge, Regina Renner, Melanie Peckruhn, Jörg Tittelbach, Dorothea Terhorst‐Molawi, Friederike Kauer, Joachim Dissemond   +6 more
wiley   +1 more source

Assessments of CYP‐Inhibition‐Based Drug–Drug Interactions Between Tofacitinib and Lipid‐Lowering Agents in Rats Both In Vitro and In Vivo

Pharmacology Research & Perspectives
Tofacitinib is a widely used medication for the treatment of arthritis. It has been reported that some patients experience abnormal cholesterol levels following treatment, leading to recommendations for the coadministration of lipid‐lowering drugs such ...
Hang Yang, Shuanghu Wang, Quan Zhou, Peiwu Geng, Zebei Lu, Qinrong Lin, Chunhong Chen, Yunfang Zhou, Jianping Cai, Dapeng Dai   +9 more
doaj   +1 more source

Manejo farmacológico de las uñas psoriásicas: revisión bibliográfica [PDF]

, 2018
[Resumen] Introducción: La psoriasis es una enfermedad cutánea hereditaria, inflamatoria y crónica, con una prevalencia mundial aproximadamente de entre el 1% y el 3%.
Domínguez González, Uxía
core  

Differences and Similarities in Clinical and Functional Responses Among Patients Receiving Tofacitinib Monotherapy, Tofacitinib Plus Methotrexate, and Adalimumab Plus Methotrexate: A Post-hoc Analysis of Data From Oral Strategy [PDF]

, 2021
Tsutomu Takeuchi, R. Fleischmann, Noriko Iikuni, Harry Shi, Koshika Soma, Jerome Paulissen, Tomohiro Hirose, Josef S Smolen   +7 more
openalex   +1 more source

Efficacy and Safety of Conventional and Biologic Therapies in Prurigo Nodularis: A Systematic Review and Meta‐Analysis

International Journal of Dermatology, EarlyView.
ABSTRACT Prurigo nodularis (PN) is a chronic, intensely pruritic skin disorder characterized by hyperkeratotic nodules and a debilitating itch–scratch cycle. Conventional therapies have limited efficacy and safety issues, while biologics have recently emerged as a promising alternative.
Andrea Lancz, Fanni Adél Meznerics, Renáta Árok, Anna Sára Lengyel, Bence Szabó, Péter Hegyi, Norbert Kiss, András Bánvölgyi   +7 more
wiley   +1 more source